300 related articles for article (PubMed ID: 28125758)
21. Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
Sharma A; Pagidipati NJ; Califf RM; McGuire DK; Green JB; Demets D; George JT; Gerstein HC; Hobbs T; Holman RR; Lawson FC; Leiter LA; Pfeffer MA; Reusch J; Riesmeyer JS; Roe MT; Rosenberg Y; Temple R; Wiviott S; McMurray J; Granger C
Circulation; 2020 Mar; 141(10):843-862. PubMed ID: 31992065
[TBL] [Abstract][Full Text] [Related]
22. Type 2 diabetes treatment and macrovascular complications--fat and sugar make a dangerous soufflé.
Bajaj M; Jialal I
Metab Syndr Relat Disord; 2009 Apr; 7(2):79-81. PubMed ID: 19351292
[No Abstract] [Full Text] [Related]
23. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies.
Meier M; Hummel M
Vasc Health Risk Manag; 2009; 5():859-71. PubMed ID: 19898642
[TBL] [Abstract][Full Text] [Related]
24. How to prevent diabetes-triggered heart disease.
An S; Zhao B; Zhang X; Liu Q
Eur J Prev Cardiol; 2018 Nov; 25(16):1789. PubMed ID: 29771157
[No Abstract] [Full Text] [Related]
25. [Hypoglycemia and cardiovascular risk].
Avogaro A
G Ital Cardiol (Rome); 2014 Dec; 15(12 Suppl 2):4S-12S. PubMed ID: 25623545
[TBL] [Abstract][Full Text] [Related]
26. Following the LEADER - why this and other recent trials signal a major paradigm shift in the management of type 2 diabetes.
Kosiborod M
J Diabetes Complications; 2017 Feb; 31(2):517-519. PubMed ID: 27839923
[TBL] [Abstract][Full Text] [Related]
27. [Intensive glycemia control of type-2 diabetes mellitus: a real A(D)VANCe or a deep dis(ACCORD)?].
Lambiel J; Fumeaux T
Rev Med Suisse; 2008 Aug; 4(166):1734. PubMed ID: 18777740
[No Abstract] [Full Text] [Related]
28. Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.
Gadde KM; Vetter ML; Iqbal N; Hardy E; Öhman P;
Diabetes Obes Metab; 2017 Jul; 19(7):979-988. PubMed ID: 28205322
[TBL] [Abstract][Full Text] [Related]
29. The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects.
Vettor R; Inzucchi SE; Fioretto P
Diabetologia; 2017 Mar; 60(3):395-398. PubMed ID: 28074254
[No Abstract] [Full Text] [Related]
30. Fasting and post-prandial glucose and diabetic complication. A meta-analysis.
Monami M; Adalsteinsson JE; Desideri CM; Ragghianti B; Dicembrini I; Mannucci E
Nutr Metab Cardiovasc Dis; 2013 Jul; 23(7):591-8. PubMed ID: 23711419
[TBL] [Abstract][Full Text] [Related]
31. Relationship of glycaemic control and hypoglycaemic episodes to 4-year cardiovascular outcomes in people with type 2 diabetes starting insulin.
Freemantle N; Danchin N; Calvi-Gries F; Vincent M; Home PD
Diabetes Obes Metab; 2016 Feb; 18(2):152-8. PubMed ID: 26511332
[TBL] [Abstract][Full Text] [Related]
32. Intensive glycemic control: implications of the accord, advance, and VADT trials for family physicians.
Dhar GC
Can Fam Physician; 2009 Aug; 55(8):803-4. PubMed ID: 19675265
[No Abstract] [Full Text] [Related]
33. The Avandia debate: an unhappy conclusion.
Bloomgarden Z; Handelsman Y
J Diabetes; 2010 Dec; 2(4):221-2. PubMed ID: 20923505
[No Abstract] [Full Text] [Related]
34. Diabetes. Paradoxical effects of tightly controlled blood sugar.
Taubes G
Science; 2008 Oct; 322(5900):365-7. PubMed ID: 18927369
[No Abstract] [Full Text] [Related]
35. Intensified glucose control in type 2 diabetes--whose agenda?
Yudkin JS; Richter B; Gale EA
Lancet; 2011 Apr; 377(9773):1220-2. PubMed ID: 21093903
[No Abstract] [Full Text] [Related]
36. Regulatory watch: FDA issues guidance for cardiovascular risk assessment of novel antidiabetic agents.
Nat Rev Drug Discov; 2009 Feb; 8(2):99. PubMed ID: 19180100
[No Abstract] [Full Text] [Related]
37. What matters in ADVANCE and ADVANCE-ON.
Hamet P
Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():20-9. PubMed ID: 22118707
[TBL] [Abstract][Full Text] [Related]
38. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM).
Basile JN
J Diabetes Complications; 2013; 27(3):280-6. PubMed ID: 23375850
[TBL] [Abstract][Full Text] [Related]
39. Higher type 2 diabetes-related mortality when HbA1c levels are too low.
Prescrire Int; 2008 Oct; 17(97):213. PubMed ID: 19536943
[TBL] [Abstract][Full Text] [Related]
40. [Blood pressure control in patients with diabetes mellitus. Focus on postprandial blood glucose values and cardiovascular risk].
MMW Fortschr Med; 2012 Feb; 154(3):82-3. PubMed ID: 22458177
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
